People with Rett syndrome (RTT) have breathing instability in addition to other neuropathological manifestations. The breathing disturbances contribute to the high incidence of unexplained death and abnormal brain development. However, the cellular mechanisms underlying the breathing abnormalities remain unclear. To test the hypothesis that the central CO(2) chemoreception in these people is disrupted, we studied the CO(2) chemosensitivity in a mouse model of RTT. The Mecp2-null mice showed a selective loss of their respiratory response to 1-3% CO(2) (mild hypercapnia), whereas they displayed more regular breathing in response to 6-9% CO(2) (severe hypercapnia). The defect was alleviated with the NE uptake blocker desipramine (10 mg·kg(-1)·day(-1) ip, for 5-7 days). Consistent with the in vivo observations, in vitro studies in brain slices indicated that CO(2) chemosensitivity of locus coeruleus (LC) neurons was impaired in Mecp2-null mice. Two major neuronal pH-sensitive Kir currents that resembled homomeric Kir4.1 and heteromeric Ki4.1/Kir5.1 channels were identified in the LC neurons. The screening of Kir channels with real-time PCR indicated the overexpression of Kir4.1 in the LC region of Mecp2-null mice. In a heterologous expression system, an overexpression of Kir4.1 resulted in a reduction in the pH sensitivity of the heteromeric Kir4.1-Kir5.1 channels. Given that Kir4.1 and Kir5.1 subunits are also expressed in brain stem respiration-related areas, the Kir4.1 overexpression may not allow CO(2) to be detected until hypercapnia becomes severe, leading to periodical hyper- and hypoventilation in Mecp2-null mice and, perhaps, in people with RTT as well.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174562PMC
http://dx.doi.org/10.1152/ajpcell.00334.2010DOI Listing

Publication Analysis

Top Keywords

mecp2-null mice
16
co2 chemosensitivity
12
central co2
8
chemosensitivity mouse
8
mouse model
8
rett syndrome
8
overexpression kir41
8
co2
7
kir41
5
disruption central
4

Similar Publications

Rett syndrome (RTT) is a severe neurodevelopmental disorder primarily caused by mutations in the methyl-CpG binding protein 2 () gene. Despite advancements in research, no cure exists due to an incomplete understanding of the molecular effects of MeCP2 deficiency. Previous studies have identified impaired tropomyosin receptor kinase (Trk) neurotrophin (NTP) signaling and mitochondrial redox imbalances as key drivers of the pathology.

View Article and Find Full Text PDF
Article Synopsis
  • * Research indicates that the synthetic compound Trofinetide and nerve growth factor (rhNGF) may provide therapeutic benefits, as seen in both cell cultures and in vivo studies with mice lacking MECP2.
  • * Positive results from treatments with rhNGF showed improved cognitive and motor abilities in both male and female mouse models of Rett syndrome, with further analysis planned to explore underlying molecular mechanisms.
View Article and Find Full Text PDF

Human microglial cells as a therapeutic target in a neurodevelopmental disease model.

Stem Cell Reports

August 2024

University of California, San Diego, School of Medicine, Department of Pediatrics/Rady Children's Hospital San Diego, Department of Cellular & Molecular Medicine, La Jolla, CA 92037, USA; University of California, San Diego, Kavli Institute for Brain and Mind, Center for Academic Research and Training in Anthropogeny (CARTA), La Jolla, CA 92093, USA. Electronic address:

Article Synopsis
  • Microglia, although typically known for their immune functions in the central nervous system, also play crucial roles in brain development that are not yet fully understood, especially in humans.
  • Researchers used human microglia-like cells with a deleted MECP2 gene to study its impact, discovering that this disruption led to significant issues in cell functions like phagocytosis and synapse formation.
  • A drug called ADH-503 was found to enhance phagocytosis and restore normal synapse formation, offering potential new treatment options for conditions linked to MECP2 abnormalities in mice.
View Article and Find Full Text PDF

RIPK1 activation in Mecp2-deficient microglia promotes inflammation and glutamate release in RTT.

Proc Natl Acad Sci U S A

February 2024

Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 201203, China.

Rett syndrome (RTT) is a devastating neurodevelopmental disorder primarily caused by mutations in the methyl-CpG binding protein 2 (Mecp2) gene. Here, we found that inhibition of Receptor-Interacting Serine/Threonine-Protein Kinase 1 (RIPK1) kinase ameliorated progression of motor dysfunction after onset and prolonged the survival of Mecp2-null mice. Microglia were activated early in myeloid Mecp2-deficient mice, which was inhibited upon inactivation of RIPK1 kinase.

View Article and Find Full Text PDF

Adenosinergic System and BDNF Signaling Changes as a Cross-Sectional Feature of RTT: Characterization of Heterozygous Mouse Females.

Int J Mol Sci

November 2023

Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal.

Rett Syndrome is an X-linked neurodevelopmental disorder (RTT; OMIM#312750) associated to mutations. MeCP2 dysfunction is seen as one cause for the deficiencies found in brain-derived neurotrophic factor (BDNF) signaling, since BDNF is one of the genes under MeCP2 jurisdiction. BDNF signaling is also dependent on the proper function of the adenosinergic system.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!